Glaukos (GKOS) Competitors $93.07 +3.00 (+3.33%) As of 04/14/2025 03:59 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock GKOS vs. SOLV, SNN, PEN, STVN, NARI, INSP, BLCO, SLNO, IRTC, and PRCTShould you be buying Glaukos stock or one of its competitors? The main competitors of Glaukos include Solventum (SOLV), Smith & Nephew (SNN), Penumbra (PEN), Stevanato Group (STVN), Inari Medical (NARI), Inspire Medical Systems (INSP), Bausch + Lomb (BLCO), Soleno Therapeutics (SLNO), iRhythm Technologies (IRTC), and PROCEPT BioRobotics (PRCT). These companies are all part of the "medical equipment" industry. Glaukos vs. Solventum Smith & Nephew Penumbra Stevanato Group Inari Medical Inspire Medical Systems Bausch + Lomb Soleno Therapeutics iRhythm Technologies PROCEPT BioRobotics Glaukos (NYSE:GKOS) and Solventum (NYSE:SOLV) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, profitability, dividends, analyst recommendations, valuation, institutional ownership, community ranking and media sentiment. Is GKOS or SOLV more profitable? Solventum has a net margin of 0.00% compared to Glaukos' net margin of -39.04%. Solventum's return on equity of 0.00% beat Glaukos' return on equity.Company Net Margins Return on Equity Return on Assets Glaukos-39.04% -16.53% -10.61% Solventum N/A N/A N/A Does the MarketBeat Community believe in GKOS or SOLV? Glaukos received 450 more outperform votes than Solventum when rated by MarketBeat users. Likewise, 65.08% of users gave Glaukos an outperform vote while only 4.17% of users gave Solventum an outperform vote. CompanyUnderperformOutperformGlaukosOutperform Votes45165.08% Underperform Votes24234.92% SolventumOutperform Votes14.17%Underperform Votes2395.83% Which has stronger earnings & valuation, GKOS or SOLV? Solventum has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Solventum, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGlaukos$383.48M13.73-$134.66M-$2.87-32.43Solventum$8.25B1.42$475.76M$2.7524.69 Do analysts prefer GKOS or SOLV? Glaukos currently has a consensus price target of $159.50, indicating a potential upside of 71.38%. Solventum has a consensus price target of $79.86, indicating a potential upside of 17.63%. Given Glaukos' stronger consensus rating and higher possible upside, research analysts plainly believe Glaukos is more favorable than Solventum.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Glaukos 1 Sell rating(s) 0 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 2.92Solventum 1 Sell rating(s) 8 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media refer more to GKOS or SOLV? In the previous week, Solventum had 3 more articles in the media than Glaukos. MarketBeat recorded 12 mentions for Solventum and 9 mentions for Glaukos. Solventum's average media sentiment score of 1.38 beat Glaukos' score of 0.91 indicating that Solventum is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Glaukos 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Solventum 11 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Do institutionals & insiders have more ownership in GKOS or SOLV? 99.0% of Glaukos shares are held by institutional investors. 6.4% of Glaukos shares are held by company insiders. Comparatively, 0.1% of Solventum shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. SummaryGlaukos and Solventum tied by winning 9 of the 18 factors compared between the two stocks. Remove Ads Get Glaukos News Delivered to You Automatically Sign up to receive the latest news and ratings for GKOS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GKOS vs. The Competition Export to ExcelMetricGlaukosSurgical & medical instruments IndustryMedical SectorNYSE ExchangeMarket Cap$5.26B$4.09B$5.35B$18.52BDividend YieldN/A39.53%5.11%4.25%P/E Ratio-32.4327.6221.6531.06Price / Sales13.7346.52375.8926.47Price / CashN/A51.0838.1517.54Price / Book9.845.816.444.29Net Income-$134.66M$67.09M$3.20B$1.02B7 Day Performance8.39%2.20%6.67%4.23%1 Month Performance-9.14%-6.24%-6.27%-6.79%1 Year Performance-5.25%11.06%8.56%-0.03% Glaukos Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GKOSGlaukos4.5853 of 5 stars$93.07+3.3%$159.50+71.4%-5.3%$5.26B$383.48M-32.43780Analyst ForecastPositive NewsGap DownSOLVSolventum1.677 of 5 stars$65.25-1.4%$79.86+22.4%+8.2%$11.29B$8.25B23.7322,000Positive NewsHigh Trading VolumeSNNSmith & Nephew2.3685 of 5 stars$25.71-2.3%$27.00+5.0%+9.5%$11.24B$5.81B11.9020,100News CoveragePositive NewsGap DownHigh Trading VolumePENPenumbra3.8562 of 5 stars$263.59+0.5%$294.47+11.7%+24.5%$10.15B$1.19B775.253,900Short Interest ↑Gap UpSTVNStevanato Group1.4377 of 5 stars€19.23+1.1%N/A-24.1%$5.82B$1.10B40.914,650Positive NewsNARIInari Medical0.3588 of 5 stars$79.97flat$68.00-15.0%N/A$4.68B$493.63M-59.24800INSPInspire Medical Systems4.6422 of 5 stars$149.72+5.5%$226.70+51.4%-35.4%$4.46B$802.80M86.541,246Positive NewsGap DownBLCOBausch + Lomb3.982 of 5 stars$11.86-2.1%$18.82+58.7%-14.0%$4.18B$4.79B-13.0312,500Gap DownSLNOSoleno Therapeutics4.793 of 5 stars$69.64+3.2%$99.63+43.1%+88.5%$3.19BN/A-20.9830Positive NewsHigh Trading VolumeIRTCiRhythm Technologies0.8154 of 5 stars$100.17-0.2%$119.73+19.5%-8.8%$3.15B$591.84M-27.521,790Positive NewsPRCTPROCEPT BioRobotics2.5501 of 5 stars$50.83-0.8%$94.29+85.5%+6.0%$2.79B$224.50M-26.07430Positive NewsGap DownHigh Trading Volume Remove Ads Related Companies and Tools Related Companies SOLV Alternatives SNN Alternatives PEN Alternatives STVN Alternatives NARI Alternatives INSP Alternatives BLCO Alternatives SLNO Alternatives IRTC Alternatives PRCT Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:GKOS) was last updated on 4/15/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Glaukos Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Glaukos With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy GKOS Stock Free GKOS Stock Alerts